Revolution Medicines, Inc. (RVMD) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
RVMD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RVMD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | 100.0% | -4207.1% | -3768.3% |
| 2022 | 100.0% | -730.0% | -703.0% |
| 2021 | 100.0% | -639.7% | -636.6% |
Download Data
Export RVMD earnings history in CSV or JSON format
Free sign-in required to download data
Revolution Medicines, Inc. (RVMD) Earnings Overview
As of May 6, 2026, Revolution Medicines, Inc. (RVMD) reported trailing twelve-month net income of -$1.13B, reflecting -66.2% year-over-year growth. The company earned $-5.95 per diluted share over the past four quarters.
Looking at the long-term picture, RVMD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$31M in fiscal 2017.
Revolution Medicines, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRSN (-$70M net income, -170.9% margin), ARVN (-$81M net income, -30.8% margin), BDTX ($21M net income), RVMD has comparable earnings metrics. Compare RVMD vs MRSN →
RVMD Earnings vs Peers
Earnings metrics vs comparable public companies
RVMD Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.13B | -88.5% | -$1.18B | $-5.95 | - | - |
| 2024 | -$600M | -37.5% | -$690M | $-3.58 | - | - |
| 2023 | -$436M | -75.5% | -$487M | $-3.86 | -3768.3% | -4207.1% |
| 2022 | -$249M | -32.9% | -$258M | $-3.08 | -703.0% | -730.0% |
| 2021 | -$187M | -73.0% | -$188M | $-2.47 | -636.6% | -639.7% |
| 2020 | -$108M | -126.9% | -$111M | $-1.62 | -251.6% | -257.5% |
| 2019 | -$48M | -14.1% | -$54M | $-1.31 | -95.2% | -108.2% |
| 2018 | -$42M | -34.3% | -$40M | $-1.15 | -207.2% | -200.0% |
| 2017 | -$31M | - | -$31M | $-0.85 | - | - |
Full RVMD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See RVMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RVMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RVMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRVMD — Frequently Asked Questions
Quick answers to the most common questions about buying RVMD stock.
Is RVMD growing earnings?
RVMD EPS fell to $-5.95, with earnings declining -66.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-1.1B.
What are RVMD's profit margins?
Revolution Medicines, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RVMD's earnings?
RVMD earnings data spans 2017-2025. The declining earnings trend is -66.2% YoY. Historical data enables comparison across business cycles.